Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +50

Biogen Q1 Earnings Call Highlights

- 📈 Biogen reported Q1 revenue of $2.5 billion, representing a 2% year-over-year increase.

- 💰 GAAP EPS grew significantly by 31% to reach $2.15 per share in the quarter.

- 🔄 The company is strategically reallocating spending away from legacy MS products toward growth drugs.

- ⚡ Growth product revenue surged 12% year-over-year to approximately $851 million in Q1.

- 💉 Leqembi sales increased sharply by 74% to $168 million, maintaining its position as a market leader.

- 🌍 SKYCLARYS generated $151 million in revenue, marking a 22% increase year-over-year.

- 🤝 The pending acquisition of Apellis is expected to close in Q2 2026 after regulatory approval.

- 💵 The deal will be funded by a combination of $3.6 billion in cash and $2 billion in new borrowings.

- ⏳ Acquired assets Syfovre and Empaveli are forecast to become accretive starting in 2027.

- 📉 Analysts expect an initial financial hit of roughly $120–$130 million to non-GAAP income/expense for 2026.

- 💰 Biogen generated approximately $594 million in free cash flow during the first quarter.

- 🔬 R&D spending included investments in late-stage phase III programs for felzartamab and litifilimab.

- 🏭 Management confirmed consistent outlooks with February guidance, including roughly $600 million in anticipated contract manufacturing revenue for 2026.

- ⚖️ The company stated that recent tariff announcements will not materially impact its 2026 business operations.

- 📊 Real-world data indicates nearly 80% of Leqembi patients remain on therapy at the 18-month mark.

- 🌐 SKYCLARYS is now available in 35 countries with growth anticipated from markets outside the U.S.

Bullish Signals
  • Biogen reported Q1 revenue of $2.5 billion (up 2% YoY) and GAAP EPS of $2.15 (up 31%), reflecting a strong strategic shift from legacy products to growth drugs.
  • Growth product revenue reached approximately $851 million in Q1 (up 12% YoY), surpassing the remaining multiple sclerosis portfolio for the first time.
  • Leqembi sales surged 74% to $168 million and remain the market leader in key markets including the U.S., Japan, and China.
  • Real-world data for Leqembi shows strong patient persistence, with nearly 80% of patients continuing therapy at 18 months and almost 70% at two years.
  • SKYCLARYS revenue grew 22% to $151 million globally, demonstrating expanding demand outside the U.S. as the drug is now available in 35 countries.
  • The company generated $594 million of free cash flow and ended the quarter with $4.7 billion in cash and marketable securities.
  • Leqembi is poised to initiate ahead of its May U.S. PDUFA date, maintaining its position as a market leader in key geographic regions.
  • Biogen expects underlying business outlook to remain consistent with February guidance, anticipating roughly $600 million of contract manufacturing revenue in 2026.
  • The upcoming Apellis acquisition is forecasted to be accretive starting in 2027 and will add Syfovre and Empaveli to the growth portfolio upon closing in Q2 2026.
Risk Factors
  • The company is significantly indebted with $1.5 billion in net debt, raising concerns about financial flexibility during the pending Apellis acquisition.
  • Biogen expects a hit of approximately $120–$130 million to its 2026 non-GAAP other income/expense resulting from the acquisition structure.
  • The company recorded roughly $34 million of acquired IPR&D in Q1, and is expected to incur $145 million of similar charges in Q2, impacting earnings significantly.
  • Biogen Stock Is Mutating Into a Value Play section and headers like 'Interested in Biogen Inc.? Here are five stocks we like better' suggest analysts view the stock unfavorably compared to peers.
  • SKYCLARYS U.S. revenue was impacted by inventory dynamics, though demand is strong, creating lumpy reporting patterns that complicate performance assessment.
  • Dr. Priya Singhal highlighted data showing only 'nearly 80%' of patients remaining on Leqembi at 18 months and 'almost 70%' at two years, indicating potential churn risks.
Full Analysis
Biogen (NASDAQ: BIIB) reported first-quarter 2026 results showing revenue of $2.5 billion, an increase of 2% year-over-year, with GAAP diluted earnings per share rising 31% to $2.15 and non-GAAP diluted EPS increasing 18% to $3.57. The company highlighted a strategic reallocation of spending away from legacy multiple sclerosis (MS) products toward growth-driving drugs, which generated approximately $851 million in Q1 revenue, up 12% compared to the prior year. Executives noted that for the first time, growth products surpassed MS portfolio revenue during the quarter, signaling a successful transition in resource allocation where commercial spending, previously about 90% directed toward MS in 2023, is now shifting to support expanding therapies. Key drivers of this performance were strong sales for Leqembi and SKYCLARYS. Leqembi revenue surged 74% to $168 million, maintaining its position as the market leader by patient share in the U.S., Japan, and China, while Q1 results also benefited from inventory drawdowns in China following a previous quarter's shipment buildup. SKYCLARYS grew 22% globally to $151 million, with revenue increasingly driven by expansion into 35 countries outside the United States. Leadership also presented new real-world data for Leqembi indicating high treatment persistence, with nearly 80% of patients remaining on therapy at 18 months and almost 70% at two years. Looking ahead to financial impacts and operations, Biogen is preparing for the acquisition of Apellis Pharmaceuticals, expected to close in Q2 2026 via $3.6 billion in cash and $2 billion in borrowings. The company forecasts the deal will be accretive starting in 2027 but anticipates a non-GAAP other income/expense hit of approximately $120–$130 million in 2026. Upcoming charges include about $34 million in acquired IPR&D in Q1 related to the Alcyone and Alloy transactions, with Q2 projected to incur roughly $145 million in similar charges. Additionally, the company expects approximately $600 million of contract manufacturing revenue in 2026, two-thirds of which is anticipated in the first half, while management stated that potential tariffs do not expect a material impact on its 2026 business excluding the Apellis acquisition. The pending IQLIK PDUFA decision in May will be another key milestone as the company continues to expand its late-stage pipeline with programs including felzartamab and litifilimab.